Ascendiant Capital Markets Initiates Coverage on Aclarion (NASDAQ:ACON)

Ascendiant Capital Markets started coverage on shares of Aclarion (NASDAQ:ACON) in a research note released on Monday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $1.60 price objective on the stock.

Aclarion Stock Performance

Shares of NASDAQ:ACON opened at $0.31 on Monday. The company has a fifty day simple moving average of $0.30 and a 200 day simple moving average of $0.70. Aclarion has a 12-month low of $0.27 and a 12-month high of $10.24.

Aclarion (NASDAQ:ACON) last issued its quarterly earnings results on Wednesday, May 15th. The company reported ($0.44) earnings per share (EPS) for the quarter. The company had revenue of $0.01 million during the quarter. Aclarion had a negative return on equity of 2,554.98% and a negative net margin of 10,246.33%.

Hedge Funds Weigh In On Aclarion

An institutional investor recently bought a new position in Aclarion stock. Virtu Financial LLC acquired a new position in Aclarion, Inc. (NASDAQ:ACON) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 115,183 shares of the company’s stock, valued at approximately $38,000. Virtu Financial LLC owned 1.40% of Aclarion at the end of the most recent reporting period. 7.52% of the stock is owned by institutional investors and hedge funds.

Aclarion Company Profile

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.